Show simple item record

Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study

dc.contributor.authorKrebs, Matthew G
dc.contributor.authorJohnson, M. L.
dc.contributor.authorCho, B. C.
dc.contributor.authorLee, S. H.
dc.contributor.authorKudgus-Lokken, R.
dc.contributor.authorZemlickis, D.
dc.contributor.authorMitselos, A.
dc.contributor.authorBerkay, E.
dc.contributor.authorBauml, J. M.
dc.contributor.authorKnoblauch, R. E.
dc.contributor.authorHellemans, P.
dc.contributor.authorMinchom, A.
dc.date.accessioned2023-05-17T09:50:51Z
dc.date.available2023-05-17T09:50:51Z
dc.date.issued2022en
dc.identifier.citationKrebs MG, Johnson ML, Cho BC, Lee SH, Kudgus-Lokken R, Zemlickis D, et al. Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study. Cancer Research. 2022 Jun;82(12). PubMed PMID: WOS:000892509502113.en
dc.identifier.doi10.1158/1538-7445.AM2022-CT198en
dc.identifier.urihttp://hdl.handle.net/10541/626262
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1158/1538-7445.AM2022-CT198en
dc.titleSubcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester,en
dc.identifier.journalCancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record